Barbara A Conley, MD
Barbara A. Conley, MD, is Associate Director of the Cancer Diagnosis Program (CDP) in the Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute. She is also a member of the Division’s experimental therapeutics clinic. She is currently responsible for two of NCI’s precision medicine initiatives — Exceptional Responders initiative, which aims to use nucleic acid sequencing to examine tissues from patients who had remarkable responses to systemic treatments to which few patients respond, and the NCI MATCH (Molecular Analysis for Therapy Choice) clinical trial, which will open late in 2014 through the National Clinical Trials Network and will biopsy and profile tumors from up to 3000 patients with solid tumors or lymphomas who have progressed after standard therapy and will match patients with treatments based on their molecular profiles.
Her previous positions at the Institute included Chief of the Diagnostics Research Branch (Cancer Diagnosis Program), Senior Investigator in the Clinical Investigations Branch (Cancer Therapy Evaluation Program), and Head, Aerodigestive Diseases in the intramural medicine branch. Her positions outside of NCI have included Chief of the Division of Hematology/Oncology at Michigan State University (MSU) 2005-2010, and Assistant and Associate Professor at the University of Maryland from 1987-1997. Dr. Conley has been the principal investigator on several NCI grants or contracts.
Dr. Conley holds an undergraduate degree from the University of Michigan and received her MD from Michigan State University. She is board-certified in Internal Medicine and Medical Oncology, and has research interests in diagnostic markers, drug development, and cancers of the aerodigestive tract. She has published extensively in many journals, and serves on the editorial board of several professional publications.